The GLP-1 Boom Created a $2 Billion Opening in Aesthetics. One Preclinical Biotech Is Building the Product to Fill It.

The GLP-1 Boom Created a $2 Billion Opening in Aesthetics. One Preclinical Biotech Is Building the Product to Fill It.

PR Newswire

RENO, Nev., July 15, 2026

Issued on behalf of Conexeu Sciences Inc.Conexeu Sciences Inc. (NASDAQ: CNXU) is aiming its investigational CXU™ platform at the largest unclaimed frontier in injectable aesthetics: restoring real body volume at a scale today's fillers were never built to reach, a move built on the company's completed 12-month P.R.O.O.F.™ preclinical study.RENO, Nev., July 15, 2026 /PRNewswire/ -- Equity Insider News Commentary — Every so often, a wave of demand in one corner of medicine spills over and creates an entirely new market next door. The GLP-1 weight-loss boom is doing exactly that. As roughly 1 in 8 U.S. adults have now used a GLP-1 medication and millions reshape their bodies, a second-order demand has appeared: restoring the natural fullness that rapid weight loss leaves behind. Boston Consulting Group projects provider revenue from GLP-1-related aesthetic care will nearly triple, from about $0.7 billion to $2.0 billion by 2030. Conexeu Sciences Inc. (NASDAQ: CNXU), a preclinical-stage biotechnology company, is aiming its investigational CXU™ tissue-restoration platform at precisely that opening.